**Part 1: Identification**

ESC Working Group on Cardiovascular Pharmacology and Drug Therapy (WG3):

Nucleus composition:
**CHAIRMAN:** Luis Miguel Ruilope, Spain  
**VICE-CHAIRMAN:** Keld Per Kjeldsen, Denmark  
**PAST-CHAIRMAN:** Faiez Zannad, France

**SECRETARY:** Maria Angeles Alonso Garcia, Spain  
**TREASURER:** Stefan Agewall, Norway  
**WEB EDITOR:** Atul Pathak, France

Ordinary nucleus members:
**Basil Lewis.** Israel  
**Franco Naccarella,** Italy  
**Giuseppe Rosano,** Italy  
**Harald Schmidt,** The Netherlands  
**Sven Wassmann,** Germany

Ex-officio nucleus members:
**Dan Atar,** Norway  
**Kurt Stoschitzky,** Austria

**Part 2: Activities of the WG during the year**

**Endorsed Meetings:**

CardioVascular Clinical Trialists Forum (CVCT) 2-3 December 2011, Paris, France, 360 participants.

Cardiovascular Spring Meeting: Antiarrhythmics and anticoagulants in atrial fibrillation 26-27 May 2012, Vienna, Austria, 35 participants.

**Papers & Guidelines:**


Guidelines / Consensus documents:

1. ESC Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. Stefan Agewall, Keld Per Kjeldsen.


6. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Faiez Zannad.


8. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Dan Atar.


Affiliated journal:

European Heart Journal accepted to renew the affiliation of the Journal "Fundamental and Clinical Pharmacology" with the ESC and the Publications Committee in particular (continuation of affiliation in 2012). Editor Atul Pathak. Fundamental and Clinical Pharmacology is endorsed by WG3.

Sessions at ESC 2011 Congress Paris, France:

1. Are there geographical variations in outcome trials?

2. The myth of class effects

3. Controversial issues in diabetes management

4. Controversies in acute coronary syndrome

5. Autonomic nervous system and humoral regulations

Part 3: Future projects / business plan
Position Papers


3. What is the optimum potassium concentration and how to ensure it? Under discussion. Responsible author: Keld Per Kjeldsen.

Meetings:

Sessions at ESC 2012 Congress Munich, Germany:

1. Seminars and symposia accepted: Lessons learned from negative trials
2. The class effect myth: Are all drugs in a class created equal
3. Do we really use statins adequately
4. What is optimum potassium concentration and how to obtain it.
5. Influencing sudden cardiac death by pharmacotherapy
6. Safety issues with cardiovascular drugs
7. Off target – Chemotherapeutics and the cardiovascular system
8. Cardiovascular pharmacotherapy in the elderly – can a patient be too old to receive cardiovascular drug treatment

Pharmacotherapy for CV disease in pregnancy

Ordinary nucleus meeting 26 August 2012, Munich, Germany

WG general assembly 27 August 2012, Munich, Germany

Extraordinary nucleus meeting 29-30 November 2012, Paris, France

CardioVascular Clinical Trialists Forum (CVCT) 30 November - 1 December 2012, Paris, France

Additional scientific meetings as well as a position paper meeting and ad hoc meetings are in preparation.

Other projects:

1. Active Participation with scientific sessions for the 2013 ESC Congress
2. Active Participation in ESC Clinical Guidelines production 2012-2013
3. Developing an annual ESC congress on Cardiovascular Pharmacology
4. Developing an ESC textbook on Cardiovascular Pharmacology
5. Developing an ESC journal of Cardiovascular Pharmacology